Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06881894 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06881894 | EXPERIMENTAL | PF-06881894 6 mg SC |
| US-approved Neulasta | ACTIVE_COMPARATOR | US-approved Neulasta 6 mg SC |
| Name | Type | Description |
|---|---|---|
| PF-06881894 | BIOLOGICAL | pre-filled syringe 6 mg |
| US-approved Neulasta | BIOLOGICAL | pre-filled syringe 6 mg |
Inclusion Criteria: • Healthy males or females between 18 and 65 years of age (both inclusive) with body mass index between 19 and 30 kg/m2, inclusive, and body weight of not \<50 kg or \>95 kg, will be enrolled in this study. Exclusion Criteria: * Hematologic laboratory abnormalities (including ...
PF-06881894 is an investigational monoclonal antibody developed by Pfizer, Inc. (ticker PFE). It has been studied in healthy adult volunteers rather than in patients with a specific disease. The compound is in Phase 1 clinical development, and its therapeutic area and intended indications have not been publicly disclosed.
PF-06881894 is made and developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical study of the compound conducted in the United States. The asset remains an investigational agent in Pfizer's pipeline.
PF-06881894 is in Phase 1 clinical development. Its only listed trial, NCT03273842, was a Phase 1 study that has been completed. Because the program is still in early-stage clinical testing, PF-06881894 is investigational and has not been approved by the FDA for any use.
PF-06881894 has been evaluated in one clinical trial, NCT03273842, titled A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers. The Phase 1 study enrolled 422 healthy volunteers in the United States, was active-controlled and randomized, and is now completed.
PF-06881894 is a monoclonal antibody, a modality in which the molecule is designed to bind a specific molecular target. The publicly available program information does not identify the exact target or target class for PF-06881894, so its precise mechanism of action has not been disclosed.
No. PF-06881894 and US-approved Neulasta are separate products. In trial NCT03273842, PF-06881894 was compared against US-approved Neulasta as the active control in healthy volunteers, which means Neulasta served as the comparator arm rather than being the same molecule as PF-06881894.